MLMayurika Lahiri

Mayurika Lahiri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mayurika Lahiri has a total of 188 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Regioisomeric carbazole–dicyano–dioxin AIDF emitters for efficient triplet harvesting, two-photon absorption and bioimaging

    by Anwesha Bera, Madhusudan Dutta, Ajay J. Malik, Madan D. Ambhore, Mayurika Lahiri, Partha Hazra

    Three carbazole–dicyano–dioxin regioisomers exhibits AIDF with high PLQYs, fast RISC (∼10⁵ s −1 ) and tunable emission. Efficient triplet harvesting and strong charge-transfer character enable applications in converted LEDs and two-photon bioimaging.

  • Open Access

    Api5 Regulates Genomic Stability and Chemotherapy Resistance in Cancer

    by Benchamin Abraham, Ayushi Upadhyay, Khushi Malhotra, Ajay J Malik, Dhananjay Virkar, Aryaman Deshmukh, Mayurika Lahiri

    Api5 is elevated in a number of cancers and is associated with many hallmarks of cancer, including resistance to apoptosis, immune escape, stemness, chemotherapy resistance, high proliferation, and cell-cycle dysregulation. In this study, we identified the DNA and chromatin-binding activities of Api5 in tumorigenic cells, as well as its association with genomic instability and chemotherapy resistance. Knockdown of Api5 resulted in reduced nuclear volume, DNA content, and chromosome number, and increased sensitivity to DNA damage. The survival of Api5-knockdown cells decreased following UV and cisplatin treatments due to the accumulation of damaged DNA and inefficient nucleotide excision repair. Interestingly, Api5 knockdown cells also exhibited low pChk1 levels following UV damage. Further, we confirmed the chemotherapy resistance phenotype in cancers with elevated Api5 levels, demonstrating that xenograft tumours with Api5 knockdown responded better to cisplatin, with significant tumour regression.

  • Open Access

    An Atlas of Indian Genetic Diversity

    by Krithika Subramanian, Chandrika Bhattacharyya, Pratheusa Machha, Ankit Mukherjee, Devashish Tripathi, Shreya Chakraborty, Sauma Suvra Majumdar, Shouvanik Sengupta, Priyanka Singh, Vinay More, et al.

    India, the most populous country, remains significantly underrepresented in the global genomics landscape. Previous efforts to catalog Indian genetic diversity were limited in scale, scope, and representation. Here, we present the GenomeIndia dataset, comprising whole genome sequences of 9,768 healthy individuals from 83 populations spanning the ethnolinguistic and biogeographic spectrum of India. We identify 129.93 million high-confidence biallelic variants, 44.03 million of which are previously unreported in global databases. In contrast to large populations that show steady population growth and internal homogeneity, we observe low effective population sizes, significant genetic drift, and profound homozygosity in small tribal groups, likely shaped by antiquity, isolation, and endogamy. We report multiple population-specific pharmacogenomic and deleterious variants, necessitating the integration of local genetic architecture and the inclusion of underrepresented South Asian genomes in global reference resources. Finally, we highlight the limited transferability of Eurocentric polygenic scores to Indian populations, and present an imputation panel that outperforms existing resources for both rare and common variants. Together, our work fills a significant gap in the equity of global human genomics, and paves way for precision medicine strategies that will benefit a quarter of the world population.


  • Open Access

    A Doubly Caged Bis(salicylamide)-Based Anion Transporter for Phototriggered Breast Cancer Therapy

    by Naveen J. Roy, Ronedy Naorem, Benchamin Abraham, Arjun Jagdish, Parappa L. Pujari, Manzoor Ahmad, Umesh Shivpuje, Mayurika Lahiri, Pinaki Talukdar

    Formulation of ion transporters, which hold great potential for anticancer therapy, as prodrugs/protransporters can overcome their nontarget activity, allowing for local activation using specified stimuli. Photocleavable protecting groups offer a robust strategy for caging transporter activity. Their reliance on light as a stimulus ensures ease of application and precise spatiotemporal control. Thus, there is a need to develop protransporters that are activatable in the biologically benign visible region of the electromagnetic spectrum. Herein, we report a series of bis­(salicylamide)-based anion antiporters caged with o-nitrobenzyl groups to create protransporters that can be activated by 405 nm light. Active transporter release via two-step photocleavage and the subsequent photoinduced recovery of ion transport activity was verified. In vitro photoactivation of protransporters using 405 nm light efficiently induced cell death in MCF-7 and triple-negative MDA-MB-231 breast cancer cell lines.


  • JoVE Video Dataset

    by Snehal Bhatia, Mayurika Lahiri

    Breast cancer remains the most prevalent cancer among women globally, with the highest age-standardised incidence and mortality rates. Despite the advancements in therapies targeting breast cancer, 20% of the patients exhibit relapse of the disease, which may be attributed to a population of therapy-resistant cancer stem cells (CSCs). These CSCs can survive conventional treatments by remaining in a quiescent stage or persist due to incomplete resection of the tumor mass, resulting in recurrence at a later stage. Therefore, recent research has focused on identifying, isolating and targeting this resistant population of cells. In vitro, the mammosphere formation assay serves as a robust three-dimensional suspension culture system for enriching and propagating stem-like cells within breast epithelial populations. Here, we present an approach utilising the mammosphere assay to evaluate the cancer stem cell-like phenotype that is enabled in non-tumorigenic breast epithelial cells by the overexpression of Apoptosis Inhibitor 5 (Api5). The protocol involves propagating mammospheres through serial passages to assess mammosphere formation efficiency and self-renewal capacity. Additionally, protein lysates collected from mammospheres are probed for established stemness markers via immunoblotting. This assay enables the investigation of novel regulators, such as Api5, of cancer stem cell-like properties in breast epithelial cell populations. The approach described can be adapted for comparative studies of molecular interventions or for screening therapeutic agents targeting CSCs in vitro.

  • Mammosphere Assay Reveals Api5-Induced Stemness in Non-Tumorigenic Breast Epithelial Cell Lines

    by Snehal Bhatia, Mayurika Lahiri

    Breast cancer remains the most prevalent cancer among women globally, with the highest age-standardised incidence and mortality rates. Despite the advancements in therapies targeting breast cancer, 20% of the patients exhibit relapse of the disease, which may be attributed to a population of therapy-resistant cancer stem cells (CSCs). These CSCs can survive conventional treatments by remaining in a quiescent stage or persist due to incomplete resection of the tumor mass, resulting in recurrence at a later stage. Therefore, recent research has focused on identifying, isolating and targeting this resistant population of cells. In vitro, the mammosphere formation assay serves as a robust three-dimensional suspension culture system for enriching and propagating stem-like cells within breast epithelial populations. Here, we present an approach utilising the mammosphere assay to evaluate the cancer stem cell-like phenotype that is enabled in non-tumorigenic breast epithelial cells by the overexpression of Apoptosis Inhibitor 5 (Api5). The protocol involves propagating mammospheres through serial passages to assess mammosphere formation efficiency and self-renewal capacity. Additionally, protein lysates collected from mammospheres are probed for established stemness markers via immunoblotting. This assay enables the investigation of novel regulators, such as Api5, of cancer stem cell-like properties in breast epithelial cell populations. The approach described can be adapted for comparative studies of molecular interventions or for screening therapeutic agents targeting CSCs in vitro.

  • Open Access

    Api5-FGF2 regulates the transformation of breast epithelial cells via PDK1/Akt and Ras/MAPK/ERK signalling

    by Anisha Goyal, Mayurika Lahiri

    The equilibrium between cell death and cell division is crucial for maintaining tissue homeostasis in a multicellular organism. Apoptosis plays an essential role in preserving homeostasis and hence occurs in a coordinated manner. However, inhibition of apoptosis is one of the hallmarks of cancer. Apoptosis Inhibitor 5 (Api5), an anti-apoptotic protein, is upregulated in various cancers, including ovarian, bladder, cervical, and lung cancers. Studies have demonstrated that altered expression of Api5 leads to the transformation of non-tumorigenic breast epithelial cells. However, the mechanism regulating this process is not well-elucidated. Our study demonstrates that overexpression of Api5 increased FGF2 (Fibroblast Growth Factor 2) levels both at protein and transcript levels. We studied the mechanistic details of changes in morphology, proliferation, and polarity observed upon FGF2/FGFR1 deregulation in Api5-overexpressing cells. Deciphering the signalling mechanism underlying Api5-FGF2-mediated breast tumorigenesis revealed that the PDK1/Akt and Ras/MAPK/ERK pathways regulated multiple transformation phenotypes. PDK1/Akt enhanced proliferation and altered morphology during initial stages, whereas Ras/MAPK/ERK regulated polarity disruption, proliferation, and reduced apoptosis during later stages of morphogenesis. In conclusion, this study provides insights into the signalling mechanism regulating the transformation phenotypes associated with Api5 overexpression in a non-tumorigenic breast epithelial cell line.

  • Pyrrole‐Linked Benzimidazolyl Hydrazone Self‐Assembly Forms HCl Channels and Induces Apoptosis in Cancer Cells

    by Abhishek Mondal, Shreyada N. Save, Susmita Sarkar, Abhijith Kuttanamkuzhi, Sumit Bawari, Thangavel Vijayakanth, Umesh Shivpuje, Mayurika Lahiri, Jagannath Mondal, Shilpy Sharma, et al.

    Modulation of intracellular chloride ion concentration by artificially developed ion transporters has been known to induce apoptosis in cancer cells. However, most of these transporters cause harm to healthy cells as well, limiting their applicability in real biological systems. Here, we report a pyrrole‐linked benzimidazolyl‐hydrazone that self‐assembles to form a nanochannel assembly across the lipid bilayer, enabling the selective translocation of HCl, a system rarely reported in the literature. The channel shows an extraordinarily high HCl transport activity with an EC50 value as low as 0.016 mol%, relative to lipid. We demonstrate solid‐state evidence that compound 1 self‐assembles in the presence of HCl to produce organized arrays that include chloride‐filled and water‐filled channels. The formation of a stable HCl channel across the lipid bilayer membrane was verified through electrophysiological experiments, detailed molecular dynamics (MD) simulations, and quantum mechanical calculations. When tested in cellular systems, the compound showed pronounced toxicity toward cancerous cell lines while remaining relatively nontoxic to cell lines of non‐cancerous origin. Interestingly, compound 1 was also found to inhibit the growth and proliferation of MCF‐7‐derived 3D spheroids with higher efficiency when compared to the commercially available anticancer drug─doxorubicin (DOX).


  • Pyrrole‐Linked Benzimidazolyl Hydrazone Self‐Assembly Forms HCl Channels and Induces Apoptosis in Cancer Cells

    by Abhishek Mondal, Shreyada N. Save, Susmita Sarkar, Abhijith Kuttanamkuzhi, Sumit Bawari, Thangavel Vijayakanth, Umesh Shivpuje, Mayurika Lahiri, Jagannath Mondal, Shilpy Sharma, et al.

    Modulation of intracellular chloride ion concentration by artificially developed ion transporters has been known to induce apoptosis in cancer cells. However, most of these transporters cause harm to healthy cells as well, limiting their applicability in real biological systems. Here, we report a pyrrole‐linked benzimidazolyl‐hydrazone that self‐assembles to form a nanochannel assembly across the lipid bilayer, enabling the selective translocation of HCl, a system rarely reported in the literature. The channel shows an extraordinarily high HCl transport activity with an EC50 value as low as 0.016 mol%, relative to lipid. We demonstrate solid‐state evidence that compound 1 self‐assembles in the presence of HCl to produce organized arrays that include chloride‐filled and water‐filled channels. The formation of a stable HCl channel across the lipid bilayer membrane was verified through electrophysiological experiments, detailed molecular dynamics (MD) simulations, and quantum mechanical calculations. When tested in cellular systems, the compound showed pronounced toxicity toward cancerous cell lines while remaining relatively nontoxic to cell lines of non‐cancerous origin. Interestingly, compound 1 was also found to inhibit the growth and proliferation of MCF‐7‐derived 3D spheroids with higher efficiency when compared to the commercially available anticancer drug─doxorubicin (DOX).


  • Open Access

    Illuminating apoptosis: a visible light-activated chloride carrier for chloride transport and cell death

    by Manzoor Ahmad, Naveen J. Roy, Debashis Mondal, Thangavel Vijayakanth, Mayurika Lahiri, Pinaki Talukdar

    Report of 3-substituted indole-2-carboxamide ion carriers and their o -nitrobenzyl caged procarriers. Photoactivation of the 2-nitro-5-(dimethylamino)benzyl caged procarrier at 450 nm in MCF-7 cells led to ion homeostasis disruption-induced apoptosis.